3rd Medical Department with Hematology and Medical Oncology, Hemostasiology, Rheumatology and Infectiology, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Hospital Salzburg, Austria.
University Hospital, Department of Hematology, Oncology and Clinical Immunology, Düsseldorf, Germany.
Leuk Res. 2014 Apr;38(4):475-83. doi: 10.1016/j.leukres.2014.01.006. Epub 2014 Jan 18.
Recent data suggest that azacitidine may be beneficial in CMML. We report on 48 CMML-patients treated with azacitidine. Overall response rates were high (70% according to IWG-criteria, including 22% complete responses). Monocyte count and cytogenetics adversely affected survival, whereas age, WHO-type, FAB-type, and spleen size did not. Matched-pair analyses revealed a trend for higher two-year-survival for azacitidine as compared to best supportive care (62% vs. 41%, p=0.067) and longer OS for azacitidine first-line vs. hydroxyurea first-line (p=0.072, median OS 27.7 vs. 6.2 months). This report reinforces existing evidence that azacitidine is safe and efficacious in both myelodysplastic and myeloproliferative CMML.
最近的数据表明，阿扎胞苷可能对 CMML 有益。我们报告了 48 例接受阿扎胞苷治疗的 CMML 患者。总体缓解率较高（根据 IWG 标准为 70%，包括 22%的完全缓解）。单核细胞计数和细胞遗传学对生存有不利影响，而年龄、WHO 类型、FAB 类型和脾脏大小则没有。配对分析显示，与最佳支持治疗相比，阿扎胞苷的两年生存率有升高趋势（62%比 41%，p=0.067），并且阿扎胞苷一线治疗比羟基脲一线治疗的 OS 更长（p=0.072，中位 OS 27.7 比 6.2 个月）。本报告进一步证实了阿扎胞苷在骨髓增生异常和骨髓增生性 CMML 中安全有效的现有证据。
